NMN/NR and Opioids (Oxycodone, Hydrocodone, Tramadol): Interaction Guide

HealthRX.com

No human studies yet of NMN or NR with these opioids

Print or save as PDF

Key numbers

  • 9% to 17%Rise in concurrent benzodiazepine use among privately insured US adults filling opioid prescriptionsSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 250 mgNMN daily dose given for 12 weeks in one trial, not a recommended doseSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 1 g/dayNR daily dose in a 21-day trial in 12 men aged 70 to 80 that did not raise muscle NAD+Source: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 3,000 mg a dayNR daily dose over 4 weeks in people with Parkinson's disease, with no moderate or severe adverse eventsSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026

At a glance

  • What NMN and NR are / Oral dietary supplements, not FDA-approved drugs [3]
  • Injectable or IV NAD+ / A compounded product, not FDA-approved [4]
  • Opioid class / Prescription pain medicines with serious risks including misuse, abuse, addiction, overdose and death [2]
  • Labeled mixing risk / Benzodiazepines and other CNS depressants, including alcohol [2]
  • Tramadol / Metabolized in part by CYP2D6; genotype-based prescribing guidance exists [5]
  • NMN doses studied in humans (not recommended doses) / 250 mg/day for 12 weeks; 1,250 mg/day for up to 4 weeks [6][7]

What is known about each side

The evidence comes from each side separately: what the supplements do to NAD+ in people, how the opioids are handled by the body, and what the opioid warnings say about mixing them with other drugs.

What oral NMN and NR do

NMN and NR are precursors that the body converts to NAD+ [1]. Oral dosing raises NAD+ in blood in randomized trials. In a trial of 80 middle-aged adults divided among placebo and three NMN dose groups, blood NAD rose in each NMN group after 60 days of 300, 600 or 900 mg daily, highest at 600 and 900 mg [9]. A randomized crossover trial found that NR increased NAD+ metabolism in middle-aged and older adults [10]. Other trials gave 250 mg of NMN daily for 12 weeks [6] and 1,250 mg daily for up to 4 weeks [7].

A rise in blood NAD+ is not the same as a tissue effect. In a 21-day trial of 12 men aged 70 to 80, NR 1 g/day did not raise muscle NAD+, although a marker of NAD+ synthesis doubled, and mitochondrial respiration was unchanged [11]. The human trials were small and short, so long-term safety is uncertain [1].

How the opioids are handled by the body

Oxycodone is N-demethylated mainly by CYP3A4 and partly O-demethylated by CYP2D6. In healthy volunteers, metabolites from the CYP3A route accounted for 45% ± 21% of a dose in urine, CYP2D6-derived metabolites for 11% ± 6%, and 6-keto-reduction for 8% ± 6% [12].

Several opioids are metabolized to some extent by CYP2D6: codeine, tramadol, hydrocodone, oxycodone and methadone [5]. The Clinical Pharmacogenetics Implementation Consortium gives CYP2D6 genotype-based prescribing recommendations for codeine and tramadol, and describes the data for hydrocodone and oxycodone as limited or weak [5].

What the opioid warnings say about adding another drug

The FDA-required class warning on opioid analgesics covers benzodiazepines and other CNS depressants, including alcohol, with risks of extreme sleepiness, respiratory depression, coma and death [2].

The size of the benzodiazepine signal has been measured. In a claims analysis of 315,428 privately insured US adults who filled an opioid prescription between 2001 and 2013, concurrent benzodiazepine use rose from 9% to 17%, and the adjusted odds ratio for an emergency visit or hospital admission for opioid overdose was 2.14 (95% CI 2.05 to 2.24) [13]. In US veterans receiving opioids, a current benzodiazepine prescription carried an adjusted hazard ratio for overdose death of 3.86 (95% CI 3.49 to 4.26) [14]. Both studies are observational.

Questions worth asking

Choose the questions you want to keep

Regulatory status of NMN, NR and injectable NAD+

NMN and NR are sold in the US as oral dietary supplements, and neither is an FDA-approved drug [3]. For NR, FDA responded to ChromaDex's own GRAS conclusion with a letter dated 2016-08-03 and stated that it had not made its own GRAS determination [15]. For NMN, FDA's 2022 position that NMN was excluded from the supplement definition was reversed in its response to a citizen petition dated 2025-09-29; NMN is now treated as lawful in dietary supplements, with new-dietary-ingredient notification rules still applying [3]. Injectable or IV NAD+ is a compounded product, not an FDA-approved drug [4].

Safety findings in the supplement trials

Published trials report no severe adverse events with NMN up to 1,250 mg a day for up to 4 weeks [7] and no moderate or severe adverse events with NR 3,000 mg a day for 4 weeks in people with Parkinson's disease [16]. These trials were not designed to test combinations with opioids.

Check what you know

Think you have it? Try 5 quick questions and see what the article says.

1. According to the article, what is known about taking NMN or NR with oxycodone, hydrocodone or tramadol?

Question 1 of 5

Score: 0 right, 0 of 5 answered

Frequently asked questions

Do NMN or NR change CYP3A4 or CYP2D6 activity?
Human CYP, transporter or pharmacodynamic interaction studies of NMN or NR were not found, so their effects with oxycodone, hydrocodone or tramadol are unknown [1]. Tramadol is metabolized in part by CYP2D6, and genotype-based prescribing guidance exists for tramadol and codeine [5].
What do the opioid warnings say about adding another drug?
The FDA-required class warning covers benzodiazepines and other CNS depressants including alcohol, with risks of extreme sleepiness, slowed breathing, coma and death [2]. Among 315,428 privately insured opioid users, concurrent benzodiazepine use carried an adjusted odds ratio of 2.14 for an emergency visit or admission for opioid overdose [13].
Are NMN and NR the same as injectable NAD+?
No. NMN and NR are oral dietary supplements and neither is FDA-approved [3]; injectable or IV NAD+ is a compounded product, not an FDA-approved drug [4].

Reader questions

What people actually ask

Short answers drawn from the sources this article cites.

What drugs interact badly with tramadol?

Tramadol is metabolized in part by CYP2D6, and genotype-based prescribing guidance exists for it. The labeled mixing risk is benzodiazepines and other CNS depressants, including alcohol, with risks of extreme sleepiness, respiratory depression, coma and death. Whether NMN or NR interacts with tramadol is not established, since no human interaction studies were found.

What drugs interact badly with oxycodone?

Oxycodone is metabolized mainly by CYP3A4 and partly by CYP2D6. The class warning names benzodiazepines and other CNS depressants, including alcohol, as the labeled mixing risk, with risks of extreme sleepiness, respiratory depression, coma and death. No human interaction studies of NMN or NR with oxycodone were found, so any effect is unknown.

References

Show all 16 referencesHide references
  1. Freeberg KA, Udovich CC, Martens CR, Seals DR, Craighead DH. Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions. J Gerontol A Biol Sci Med Sci. 2023;78(12):2435-2448.
  2. New Safety Measures Announced for Opioid Analgesics, Prescription Opioid Cough Products, and Benzodiazepines | FDA.
  3. Official web page.
  4. FDA. Bulk Drug Substances Used in Compounding. Bulk Drug Substances Used in Compounding | FDA
  5. Crews KR, Monte AA, Huddart R, Caudle KE, Kharasch ED, Gaedigk A, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy. Clin Pharmacol Ther. 2021;110(4):888-896.
  6. Okabe K, Yaku K, Uchida Y, Fukamizu Y, Sato T, Sakurai T, et al. Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects. Front Nutr. 2022;9:868640.
  7. Fukamizu Y, Uchida Y, Shigekawa A, Sato T, Kosaka H, Sakurai T. Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women. Sci Rep. 2022;12(1):14442.
  8. Yoshino M, Yoshino J, Kayser BD, Patti GJ, Franczyk MP, Mills KF, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229.
  9. Yi L, Maier AB, Tao R, Lin Z, Vaidya A, Pendse S, et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. Geroscience. 2023;45(1):29-43.
  10. Martens CR, Denman BA, Mazzo MR, Armstrong ML, Reisdorph N, McQueen MB, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286.
  11. Elhassan YS, Kluckova K, Fletcher RS, Schmidt MS, Garten A, Doig CL, et al. Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures. Cell Rep. 2019;28(7):1717-1728.e6.
  12. Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen DD. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther. 2006;79(5):461-79.
  13. Sun EC, Dixit A, Humphreys K, Darnall BD, Baker LC, Mackey S. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. BMJ. 2017;356:j760.
  14. Park TW, Saitz R, Ganoczy D, Ilgen MA, Bohnert AS. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study. BMJ. 2015;350:h2698.
  15. Agency Response Letter GRAS Notice No. GRN 000635 | FDA.
  16. Berven H, Kverneng S, Sheard E, Søgnen M, Af Geijerstam SA, Haugarvoll K, et al. NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease. Nat Commun. 2023;14(1):7793.
Evidence overview for interactions nad nmn: NMN/NR and Opioids (Oxycodone, Hydrocodone, Tramadol): Interaction Guide